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Melanomametastaticto the appendix isextremely rare. Here we describe acaseofa 31-year-old femalefrom Bolivia witharemote
historyofmetastaticmalignantmelanomaﬁrstdiagnosedasa cutaneousmalignantmelanomaten years priorto this presentation.
The patient was being followed for a mucocele which on resection was found to be metastatic melanoma. “Mucocele” is a generic
diagnosis that warrants further characterization and treatment.
1.Introduction
Malignant melanoma involving the gastrointestinal (GI)
tract is a rare condition although it is one of the most
common malignancies having the potential to metastasize to
the GI tract [1–4]. GI metastasis are frequently found during
autopsy (50%–60% of cases), but only a small proportion of
living melanoma patients are diagnosed with GI metastasis
(2%–5%ofpatients) [5, 6]. The most common sites of mela-
noma metastasis to the GI tract are the stomach and small
intestine [7, 8].
We report a case of malignant melanoma metastatic to
the appendix presenting as acute appendicitis in the back-
ground of a mucocele.
2.CasePresentation
The patient is a 31-year-old female from Bolivia with a
history of melanoma removed from her back ten years
prior to this presentation. The pathology report was not
available. In November 2005, the patient, now living in the
USA,developedincreasing headaches, vomiting, and blurred
vision. CT scan showed a large left frontal cerebral mass
with edema and displacement of the midline structures.
The patient then underwent surgical resection of brain
tumor which was interpreted as metastatic melanoma.
After receiving palliative therapy, the patient enrolled in a
chemotherapy trial, Temozolomide along with Sorafenib, at
the University of Pennsylvania. Later in 2008, she developed
a new 4mm lesion in right frontal brain lobe. She had
no evidence of other metastases. While the patient was
being followed by serial CAT scans, a slow growing mass
was noted in the appendix approximately one year prior to
this presentation, which was interpreted as a mucocele and
managed conservatively. In April of 2010, she presented to
our institution with symptoms of acute appendicitis. A
CT scan of the abdomen and pelvis revealed inﬂammatory
changes and gas in the wall of the distended appendix
(Figure 1). The mucocele extended to the base of the cecum;
she underwent an appendectomy with partial cecectomy the
same day to achieve adequate resection margins.
Cloudy peritoneal ﬂuid was noted intraoperatively, and
the postoperative diagnosis was gangrenous appendicitis
superimposed on a mucocele. She recovered uneventfully.
On grossexamination, theappendix was 8.0cmin length




Figure 1: CT scan (coronal view) of the abdomen and pelvis
showing an appendiceal mucocele with intraluminal gas and wall
edema.
The serosal surface was smooth with areas of hyperemia,
and a focal disruption measured 1.5cm was located in mid
appendix. Sectioning revealed an 7.5cm in length with 1.4–
3.0cm in diameter tumor occupying more than 80% of
the appendix. The tumor was soft, pink/tan in the distal
aspect, and lobulated green/brown in the proximal portion
(Figure 2) . No perforation was grossly appreciated.
On microscopic examination, tumor cells replaced most
of the appendiceal mucosaand muscularis with no extension
to the serosa. The lesional cells formed nests and cords and
had an abundant eosinophilic cytoplasm with mildly pleo-
morphic nuclei and prominent nucleoli, some of which had
intranuclear inclusions (Figures 3(a) and 3(b)). The tumor
cells were positive for the melanoma markers Melanoma
Antigen (M; HMB45; Enzo; New York), Melan-A (M; A103;
C e l lM a r q u e ;C a l i f o r n i a ) ,a n dS - 1 0 0( P ;D A K O ;C a l i f o r n i a )
(Figures 3(c) and 3(d)). Acute appendicitis and periappen-
dicitis were also present. The cecum was free of disease. The
diagnosis of metastatic malignant melanoma was made. The
patient is doing well at the present time. She is alive with
the disease. Plan for followup is to continue to monitor
her metastatic melanoma and to enter patient in melanoma
vaccine trials.
3.Discussion
Malignant melanoma represents 1–3% of all cancer in the
USA [9]. Malignant melanomas develop from melanocytes
which are derived from neural crest cells. The neural crest
cells migrate during embryologic development and may be
found in noncutaneous sites. Although they usually occur in
Figure 2: Gross examination: cross-section of appendix, lobulated
green/brown partially hemorrhagic, and pigmented tumor occupy
the proximal portion of the appendiceal lumen.
theskin(cutaneousmelanoma),melanomascanoccurinany
organ in which melanin-containing cells are present [7].
Melanocytes are normal residents of the mucous mem-
branes of the upper aerodigestive tract, gastrointestinal, and
urogenital tracts [7]. These cells give rise to malignant mela-
nomas of the mucous membranes lining the GI tract. Malig-
nant melanomas involving the GI tract may be primary (i.e.,
anorectum,esophagus,andgallbladder)ormetastaticlesions
(i.e., stomach and liver) [7]. Mucosal melanomas of the
gastrointestinal tract are rare tumors that represent about
1.5%–2.0% of all melanomas [1, 7, 10]. The overwhelming
majority of malignant melanomas involving the GI tract
are secondary to metastatic disease [11]. The interval time
between diagnosis of the primary and metastatic disease is
variable (average, 7.0 years) [7]. Patients with GI metastasis
may present with bleeding, anemia, obstruction, abdominal
discomfort, pain, and intestinal perforation [7]. GI metas-
tases usually appear as multiple polypoid lesions and can
be either pigmented or amelanotic and often ulcerated [2].
Less commonly the presentation is of a solitary melanotic
tumor. Metastases to the GI tract can present both at
t h et i m eo fp r i m a r yd i a g n o s i so ry e a r sl a t e ra st h eﬁ r s t
sign of recurrence. Diagnosis of metastatic melanoma is
generally made by radiographic contrast studies, includingJournal of Oncology 3
(a) (b)
(c) (d)
Figure 3: Microscopic examination: (a) solid cords and nests of tumor cells ﬁll the appendiceal lumen and replace the appendiceal mucosa
andsubmucosawithpartialextensiontothemuscularis,noinvolvementoftheserosa;(b)tumorcells withabundanteosinophiliccytoplasm,
someofwhich are vacuolated, withpleomorphicnuclei,prominentnucleoli,andatypical mitosis(Hematoxylinandeosinstaining,(a)x200;
(b) x400). (c) Tumor cells strongly express HMB45, and (d) S-100 (HMB45 and S-100 immunostaining,x400).
CT, ultrasonography, PET scan and barium studies, and
endoscopic evaluation. The sensitivity of CT for detecting
metastases is only 60% to 70% [2, 12].
Metastatic melanoma has been observed in almost all
regions of the human body. The most common sites of
metastases were the lymph nodes (74%) and lungs (71%),
followed by the liver (58%), brain (55%), bone (49%),
adrenalglands(47%),andGItract(44%),butonly1%to4%
of them are diagnosed antemortem [3]. Two large autopsy
studies which looked at the distribution of metastases in the
GI tract are from the Roswell Park Memorial Institute and
Memorial Sloan Kettering Cancer Center. The distribution
of GI organ metastases in both series was as follows: liver,
58–60%; peritoneum, 43%; pancreas, 38%; small bowel,
36–58%; spleen, 31%; colon, 22–28%; stomach, 20–23%;
duodenum, 12%; rectum, 5%; esophagus, 4%; biliary tract,
9% [3, 5]. None of these studies or any others that we could
ﬁnd documented appendiceal involvement by metastatic
melanoma.
We found one reported case describing a malignant
melanoma in the vicinity of the appendix. The reported
case was that of a 55-year-old Caucasian woman with no
available medical history who presented with abdominal
pain. Ultrasound suggested a periappendicular abscess or a
tumor, but no other intraabdominal lesion was identiﬁed.
ThetumorcellsinthatcasewerepositiveforMelan-A,S-100,
HMB45, and vimentin. No primary source of melanoma in
this case was evident [13].
The prognosis of metastatic GI malignant melanoma is
very poor with a 5-year survival of less than 10% [2, 14].
However, with surgical resection there may be a possibility
of long-term, disease-free survival. Surgical resection of
distance metastasis is still the mainstay of treatment. Studies
have shown that surgical resection for melanoma metastatic4 Journal of Oncology
to the GI tract may be eﬀective for palliation and may also
result in long-term survival in selected patients [4].
4.Conclusion
Preoperative diagnosis of appendiceal metastases from ma-
lignant melanoma is diﬃcult but should be considered in
any patient with a history of melanoma who develops GI
symptoms, even in the absence of radiographic ﬁndings.
Mucocele of the appendix should be managed with resection
to ascertain its pathologic features and prevent pseudomyx-
oma peritonei or other complications.
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